Edwards Lifesciences
(NYSE: EW)
today announced new economic and clinical evidence on severe aortic stenosis (AS).
Presented at EuroPCR 2025 in Paris, data further contributes to the company’s extensive body of research on the disease. Results from the real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outcomes.
Prompt intervention for severe AS patients before symptoms developed resulted in significantly lower healthcare costs at one year. Edwards said costs registered at $36,000 less per patient. They also reported shorter stay lengths during treatment (2.2 fewer days). Patients had fewer follow-up heart failure hospitalizations one year after treatment, too (80% less).
Compared with asymptomatic severe AS, delaying treatment until the disease progressed resulted in a more than seven times higher rate of death within one year after aortic valve replacement.
Findings reinforced the value of early referral and evaluation demonstrated by Edwards’ EARLY TAVR trial results shared in March.
“We are dedicated to advancing robust evidence to help improve outcomes for patients with severe aortic stenosis,” said Larry Wood, Edwards’ corporate vice president and group president, Transcatheter Aortic Valve Replacement and Surgical. “These latest findings underscore the importance of early referral to a Heart Valve Team and timely care of patients with severe AS, reducing the economic and resource burden for hospitals.”
